Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals | Seeking Alpha
Puma Biotechnology
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
News Release Puma Biotechnology Reports Third Quarter 2012
PumaBiotech (@pumabiotech) / Twitter
SEC charges former Puma biotech exec with $1.1 million in insider trading
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
Puma Biotechnology
Puma Biotechnology falls more than 20%
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology, Inc: Upgraded Ratings and Insider Trading Revelations - Best Stocks
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
PumaBiotech on Twitter: "Puma Biotechnology is dedicated to developing innovative, new treatments to help #cancer patients. As part of our ongoing commitment to the cancer community, we're proud to have participated in #
Puma Biotechnology 獲Alisertib 授權，與武田共創雙贏! | GeneOnline News
Puma Biotechnology Surging
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
